Overall rank by patents
#26,113
of 50,000 tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 12 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
According to USPTO PatentsView, Delta-fly ranks #26,113 of 50,000 tracked US assignees by granted-patent volume, with 10 patents across 12 technology areas.
USPTO PatentsView assignee plate
Corpus R26113 · Foreign Corporation #26,113 · 10 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Datorama Technologies Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Delta-fly Pharma · this assignee
43 score
3D Lighting Innovati… · lowest
7 score
What this shows Delta-fly's Innovation Score is 43.3/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Delta-fly Pharma, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 100% of grants classified under A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2017. By volume, Delta-fly sits between Datorama Technologies Ltd. and Diamanti, Inc..
Delta-fly Pharma, Inc. shows 5 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Datorama Technologies Ltd.
10 patents
Daymen US, Inc.
10 patents
Decibel Therapeutics, Inc.
10 patents
Defender Screens International, LLC
10 patents
Design Blue Ltd.
10 patents
Destiny Software Productions Inc.
10 patents
DeviceFidelity, Inc.
10 patents
Diamanti, Inc.
10 patents
Delta-Fly Pharma, Inc.
10 patents
What this shows Delta-fly holds 10 patents at rank #26,144, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #26,144 in granted patent volume.
Other assignees with the most granted patents in Delta-fly's primary technology class.
Delta-fly's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
43 Top 28% higher than 72% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 10.0% |
| 2018 | 2 | 20.0% |
| 2019 | 1 | 10.0% |
| 2021 | 1 | 10.0% |
| 2022 | 2 | 20.0% |
| 2023 | 2 | 20.0% |
| 2024 | 1 | 10.0% |
Top 12 of 12 technology areas
Overall rank by patents
#26,113
of 50,000 tracked assignees
43.3 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.